Towards a Patent Pool for HIV Medicines: The Background

Hdl Handle:
http://hdl.handle.net/10144/114125
Title:
Towards a Patent Pool for HIV Medicines: The Background
Authors:
Childs, Michelle
Journal:
The Open AIDS journal
Abstract:
Recent WHO guidelines for antiretroviral therapy recommend switching to less toxic, but more expensive medicines for first-line and second-line ART, raising questions about the financial sustainability of many AIDS treatment programmes. At the same time, many key generic producing countries such as India now grant pharmaceutical product patents so competition between multiple manufacturers will not be able to play the role it has in bringing down the price of newer drugs.Overcoming these patent barriers will require a range of solutions, such as restricting patentability criteria, or compulsory licensing. One additional systematic solution is provided by the patent pool, a collective solution to the management of patent rights, initially presented by Médecins Sans Frontières to the French Foreign Ministry and subsequently the UNITAID Executive Board in 2006.A patent pool must not be implemented at any costs, but answer medical needs, be based on economic realities and meet the access needs of the developing world, including middle-income countries.
Affiliation:
Campaign for Access to Essential Medicines, Médecins Sans Frontières, Geneva, Switzerland
Issue Date:
1-Jul-2010
URI:
http://hdl.handle.net/10144/114125
DOI:
10.2174/1874613601004020033
PubMed ID:
20148090
Additional Links:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817875/?tool=pubmed
Type:
Article
Language:
en
ISSN:
1874-6136
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorChilds, Michelleen
dc.date.accessioned2010-10-29T14:19:04Z-
dc.date.available2010-10-29T14:19:04Z-
dc.date.issued2010-07-01-
dc.identifier.citationOpen AIDS J. 2010 Jan 19;4:33-6en
dc.identifier.issn1874-6136-
dc.identifier.pmid20148090-
dc.identifier.doi10.2174/1874613601004020033-
dc.identifier.urihttp://hdl.handle.net/10144/114125-
dc.description.abstractRecent WHO guidelines for antiretroviral therapy recommend switching to less toxic, but more expensive medicines for first-line and second-line ART, raising questions about the financial sustainability of many AIDS treatment programmes. At the same time, many key generic producing countries such as India now grant pharmaceutical product patents so competition between multiple manufacturers will not be able to play the role it has in bringing down the price of newer drugs.Overcoming these patent barriers will require a range of solutions, such as restricting patentability criteria, or compulsory licensing. One additional systematic solution is provided by the patent pool, a collective solution to the management of patent rights, initially presented by Médecins Sans Frontières to the French Foreign Ministry and subsequently the UNITAID Executive Board in 2006.A patent pool must not be implemented at any costs, but answer medical needs, be based on economic realities and meet the access needs of the developing world, including middle-income countries.en
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817875/?tool=pubmeden
dc.rightsArchived with thanks to The Open AIDS Journalen
dc.subject.meshHIV/AIDSen
dc.subject.meshpatentsen
dc.titleTowards a Patent Pool for HIV Medicines: The Backgrounden
dc.typeArticleen
dc.contributor.departmentCampaign for Access to Essential Medicines, Médecins Sans Frontières, Geneva, Switzerlanden
dc.identifier.journalThe Open AIDS journalen
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.